Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders

Objectives: To investigate the effect of topiramate on the steadystate plasma concentrations of the second-generation antipsychoticsVclozapine, olanzapine, risperidone, and quetiapineVin patients with schizophrenia or bipolar disorder. Methods: Thirty-eight outpatients on long-term treatment with clozapine (250Y500 mg/d, n = 10), olanzapine (10Y20 mg/d, n = 12), risperidone (3Y6 mg/d, n = 9), or quetiapine (200Y600 mg/d, n = 7) received adjunctive topiramate, gradually titrated up to a final dosage of 200 mg/d for 6 weeks. Pharmacokinetic assessments were made at baseline and at the end of treatment weeks 4 and 8 at topiramate dosages of 100 and 200 mg/d, respectively. Results: Plasma concentrations of clozapine and its metabolite (norclozapine), olanzapine, risperidone and its metabolite (9-hydroxy-risperidone), and quetiapine were not significantly modified during concomitant administration of topiramate. Adjunctive topiramate therapy was well tolerated in all groups. Conclusions: These findings indicate that topiramate, at the dosages recommended for use as a mood stabilizer, does not affect the plasma levels of the new antipsychoticsVclozapine, olanzapine, risperidone, and quetiapine